Atrium Therapeutics, Inc. Common Stock (RNA) Stock
NASDAQ · RNA
Key stats
- Market cap
- $136.16M
- Price / Earnings ratio
- -2.8x
- Volume
- Loading
- 52-week high
- $73.06
- 52-week low
- $7.49
Source: third-party data provider, as of November 13, 2026
Compare with RNA
Recent news

Reuters
Pharma sector doubles down on AI amid hopes of slashing costs, timelines
RNAJanuary 15, 2026
Reuters
Pharma sector doubles down on AI amid hopes of slashing costs, timelines
RNA

Zacks Investment Research
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
RNAOctober 28, 2025
Zacks Investment Research
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
RNA

Proactive Investors
Novartis to acquire Avidity Biosciences in $12B deal
RNAOctober 27, 2025
Proactive Investors
Novartis to acquire Avidity Biosciences in $12B deal
RNA

Investopedia
5 Things to Know Before the Stock Market Opens
RNAOctober 27, 2025
Investopedia
5 Things to Know Before the Stock Market Opens
RNA
Technical indicators
- RSI 14
- 39.16
- MACD 12/26/9
- -0.14
- EMA 9 of MACD
- -0.20
- MACD histogram
- 0.06
- SMA 50
- $8.92
- Price below SMA 50
- EMA 50
- $9.11
- Price below EMA 50
- SMA 200
- $18.30
- Price below SMA 200
- EMA 200
- $24.10
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Strong Sell0
Sell0
Hold0
Buy2
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2023
2024
2025
22M15M7M0
Debt & Balance Sheet
Total assets
Total liabilities
2023
2024
2025
97M64M32M0
Revenue to Profit
2025$18.6M
Revenue$0.0
Cost of revenue$18.6M
Gross profit$0.0
Operating expenses$-49.5M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Reuters
Pharma sector doubles down on AI amid hopes of slashing costs, timelines
RNAJanuary 15, 2026
Reuters
Pharma sector doubles down on AI amid hopes of slashing costs, timelines
RNA

Zacks Investment Research
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
RNAOctober 28, 2025
Zacks Investment Research
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
RNA

Proactive Investors
Novartis to acquire Avidity Biosciences in $12B deal
RNAOctober 27, 2025
Proactive Investors
Novartis to acquire Avidity Biosciences in $12B deal
RNA

Investopedia
5 Things to Know Before the Stock Market Opens
RNAOctober 27, 2025
Investopedia
5 Things to Know Before the Stock Market Opens
RNA

CNBC
Trump's trade deals, Novartis acquires Avidity, Taco Bell's beverage push and more in Morning Squawk
RNAOctober 27, 2025
CNBC
Trump's trade deals, Novartis acquires Avidity, Taco Bell's beverage push and more in Morning Squawk
RNA

Reuters
Novartis shares slip, Avidity soars after $12 billion biotech deal
RNAOctober 27, 2025
Reuters
Novartis shares slip, Avidity soars after $12 billion biotech deal
RNA

Bloomberg Markets and Finance
Novartis Agrees $12 Billion Biotech Deal for Avidity
RNAOctober 27, 2025
Bloomberg Markets and Finance
Novartis Agrees $12 Billion Biotech Deal for Avidity
RNA

New York Post
Novartis to acquire Avidity Biosciences for about $12B
RNAOctober 26, 2025
New York Post
Novartis to acquire Avidity Biosciences for about $12B
RNA

Reuters
Novartis to acquire Avidity Biosciences for $12 billion
RNAOctober 26, 2025
Reuters
Novartis to acquire Avidity Biosciences for $12 billion
RNA

CNBC
Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports
RNAOctober 26, 2025
CNBC
Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports
RNA
About Atrium Therapeutics, Inc. Common Stock
Biotechnology
SectorHealthcare
IndustryBiotechnology
Employees511
CEOMs. Kathleen P. Gallagher
IPO DateJun 12, 2020
HeadquartersSan Diego, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Kathleen P. Gallagher | President, CEO & Director | 1981 |
| Mr. Brendan Winslow | Chief Financial Officer | 1988 |
| Dr. Husam Younis Ph.D., Pharm.D. | Chief Scientific Officer | 1974 |
| Ms. Stephanie Kenney | Chief Corporate Affairs Officer | 1978 |
| Dr. Steven George Hughes M.B.A., M.D. | Chief Medical Officer | 1967 |
| Ms. Rocio Martin Hoyos | Chief Strategy Officer | 1983 |
Fundamentals
Valuation
Price-to-sales ratio12.92
Price-to-book value0.66
PEG ratio0.00
Profitability
Gross margin (latest quarter)100.00%
EBITDA$-48.75M
Trading
Average volume217,631
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 39.16
- MACD 12/26/9
- -0.14
- EMA 9 of MACD
- -0.20
- MACD histogram
- 0.06
- SMA 50
- $8.92
- Price below SMA 50
- EMA 50
- $9.11
- Price below EMA 50
- SMA 200
- $18.30
- Price below SMA 200
- EMA 200
- $24.10
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
100% Buy
0% Hold
0% Sell
Analyst price target
- Low
- $15.00
- Average
- $17.50
- High
- $20.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -9.6 | +4.3 | ||||||||||
| 2022 | -30.1 | +0.5 | +13.0 | -28.5 | -7.7 | +16.1 | +5.4 | +25.6 | -22.9 | -8.5 | -17.9 | +99.7 |
| 2023 | +17.0 | -1.0 | -36.9 | -19.4 | -13.7 | +2.0 | -16.2 | -20.6 | -19.8 | -13.3 | +52.5 | +11.7 |
| 2024 | +33.5 | +50.7 | +26.9 | -8.6 | +4.1 | +51.8 | +10.4 | -1.3 | +12.1 | -12.9 | +2.8 | -29.6 |
| 2025 | +5.6 | -4.1 | +1.0 | +22.1 | -5.2 | -14.4 | +29.0 | +29.7 | -7.7 | +62.4 | +2.7 | +1.1 |
| 2026 | +0.7 | -79.7 | -10.3 | -5.2 | -3.2 | +6.1 | -14.7 | +17.6 | -39.9 | +1.6 | -3.7 |
Compare stocks
Market cap
$136.16M
-
-
-
Price / Earnings ratio
-2.80
-
-
-
Price / Sales ratio
12.92
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
217,631
-
-
-
Earnings per share
-
-
-



